Merck, Schering-Plough report strong second-quarter sales

Share this article:

Merck and Schering-Plough each reported strong second-quarter sales results today.

Merck's second-quarter highlights included:
*Growth in global sales for asthma and allergic rhinitis treatment Singulair by 15% to $1.1 billion. 
*Global sales growth of antihypertensive medicines Cozaar and Hyzaar of 8% to $847 million.
*Global sales of $358 million for cervical cancer vaccine Gardasil.
*Global sales of $144 million for Januvia, Merck's first-in-class treatment for Type 2 diabetes.

Meanwhile, Schering-Plough's second-quarter sales increased by 13%, to almost $3.2 billion, as the company continues to benefit from a leadership turnaround under Fred Hassan.

Schering-Plough's second-quarter highlights included:
*A global sales increase for arthritis drug Remicade of 28% to $394 million.
*A global sales increase for allergy treatment Nasonex of 22% to $295 million.
*A global sales increase for seasonal allergic rhinitis drug Clarinex to $250 million from $226 million.
*International sales growth for Temodar, a treatment for certain types of brain tumors of 26% to $216 million.
*An increase in sales of Pegintron for hepatitis C of 3% to $234 million, due to higher sales in Latin America and Europe, and tempered by lower sales in the United States and Japan.

Merck and Schering-Plough's quarterly performance was helped by the joint venture between the companies to market cholesterol drugs Vytorin and Zetia. Sales of the drugs rose $1.3 billion in the quarter, up 30% from a year earlier.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.